UBX1325 met safety and efficacy endpoints at 24 weeks in the phase 2 BEHOLD study in patients with diabetic macular edema, according to a press release from Unity Biotechnology.
After a single injection of the investigational compound, subjects experienced an increase in best corrected visual acuity of 6.2 ETDRS letters at 24 weeks, which represented an improvement of 7.6 ETDRS letters over sham-treated subjects from baseline (P = .0084).
Subjects in the treatment arm also maintained central subfield thickness, while those in the sham arm demonstrated a worsening of central subfield thickness.